(±)-pavine | 52437-08-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 栗碱生物碱
• 英文名称: (±)-pavine
• 英文别名: Eschscholtzidin；(+/-)-Eschscholtzidine；8,9-dimethoxy-14-methyl-5,6,11,12-tetrahydro-5r,11c-epiazano-benzo[5',6']cycloocta[1',2':4,5]benzo[1,2-d]dioxole；15,16-dimethoxy-20-methyl-5,7-dioxa-20-azapentacyclo[10.7.1.02,10.04,8.013,18]icosa-2,4(8),9,13,15,17-hexaene
• CAS: 52437-08-8
• 化学式: C₂₀H₂₁NO₄
• 分子量: 339.391
• InChiKey: YTZIQRTXKBDFKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  40.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (±)-pavine 、 间氯过氧苯甲酸 生成 15,16-Dimethoxy-20-methyl-20-oxido-5,7-dioxa-20-azoniapentacyclo[10.7.1.02,10.04,8.013,18]icosa-2,4(8),9,13,15,17-hexaene
  参考文献：
  名称：

  LU, SHENG-TEH;WU, YANG-CHANG;LEOU, SHIOW-PIAW, J. CHIN. CHEM. SOC., 34,(1987) N 1, 33-42

  摘要：

  DOI：
• 作为产物：
  描述：

  5-(3-benzyloxy-4-methoxy-benzyl)-6-methyl-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinoline 在 甲酸 、 磷酸 作用下， 以 甲醇 、 乙醚 、 氯仿 为溶剂， 反应 2.0h， 生成 (±)-pavine
  参考文献：
  名称：

  Natarajan,S.; Pai,B.R., Indian Journal of Chemistry, 1974, vol. 12, p. 550 - 553

  摘要：

  DOI：

文献信息

• PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS
  申请人：President and Fellows of Harvard College

  公开号：EP3485881A1

  公开（公告）日：2019-05-22

  The present invention relates to a composition, optionally a pharmaceutical composition, comprising cysteine-derived compounds as defined in Formula (XII). The compound may be used in a method for treating neurogenic inflammation in a human patient.

  本发明涉及一种组合物，也可以是一种药物组合物，其中包含如式（XII）所定义的半胱氨酸衍生化合物。该化合物可用于治疗人类患者神经源性炎症的方法中。
• COMPOSITION COMPRISING MELATONIN, PIPERINE AND VITAMIN D, CONTROLLED-RELEASE FORMULATION AND USE THEREOF FOR THE TREATMENT OF SLEEP DISORDERS
  申请人：Uriach Consumer Healthcare, S.L.

  公开号：EP4019017A1

  公开（公告）日：2022-06-29

  The present invention related to a composition comprising at least melatonin, piperine and vitamin D and a controlled-release formulation thereof for the treatment of sleep disorders. The controlled-release formulation of the present invention comprises a fast release composition to promote a rapid sleep onset, a medium release composition that contributes to a restorative sleep, and a prolonged release composition that provides a good quality sleep during the night.

  本发明涉及一种至少包含褪黑素、胡椒碱和维生素D的组合物及其控释制剂，用于治疗睡眠障碍。本发明的控释制剂包括促进快速入睡的快速释放组合物、有助于恢复睡眠的中等释放组合物以及在夜间提供优质睡眠的长效释放组合物。
• Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids
  申请人：Antheia, Inc.

  公开号：US10544420B2

  公开（公告）日：2020-01-28

  The present disclosure provides systems and methods for increasing production of an alkaloid product through the epimerization of a (S)-1-benzylisoquinoline alkaloid to a (R)-1-benyzlisoquinoline alkaloid via an engineered epimerase in an engineered host cell. A (S)-1-benzylisoquinoline alkaloid is contacted with said engineered epimerase. Contacting said (S)-1-benzylisoquinoline alkaloid with said engineered epimerase converts said (S)-1-benzylisoquinoline alkaloid to said (R)-1-benzylisoquinoline alkaloid.

  本公开提供了通过工程宿主细胞中的工程表聚酶将(S)-1-苄基异喹啉生物碱表聚为(R)-1-苄基异喹啉生物碱来提高生物碱产品产量的系统和方法。将(S)-1-苄基异喹啉生物碱与所述工程表聚酶接触。将所述(S)-1-苄基异喹啉生物碱与所述工程表聚酶接触，将所述(S)-1-苄基异喹啉生物碱转化为所述(R)-1-苄基异喹啉生物碱。
• Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
  申请人：Children's Medical Center Corporation

  公开号：US10729664B2

  公开（公告）日：2020-08-04

  The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation.

  本发明提供了用于治疗神经源性炎症的化合物、组合物、方法和试剂盒。
• Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
  申请人：Antheia, Inc.

  公开号：US10738335B2

  公开（公告）日：2020-08-11

  A method of demethylizing an opioid to a nor-opioid is provided. The method comprises contacting an opioid with at least one enzyme. Contacting the opioid with the at least one enzyme converts the opioid to a nor-opioid. A method of converting a nor-opioid to a nal-opioid is provided. The method comprises contacting a nor-opioid with at least one enzyme. Contacting the nor-opioid with the at least one enzyme converts the nor-opioid to a nal-opioid.

  本发明提供了一种将阿片类药物去甲基化为非阿片类药物的方法。该方法包括将阿片类药物与至少一种酶接触。将阿片与至少一种酶接触可将阿片转化为去甲阿片。提供了一种将去甲阿片转化为正阿片的方法。该方法包括将去甲阿片与至少一种酶接触。将去甲阿片与至少一种酶接触可将去甲阿片转化为正阿片。